


Organized by: Oncology Center of Biomedical Education and Research
Oncology Unit GPP, Athens School of Medicine

3rd LUNG CANCER Network

«From the Bench to the Bedside»



FINAL PROGRAM

31st JANUARY - 1st FEBRUARY 2014

Hilton Athens Hotel, Athens, Greece

Accreditation from:
European Society for Medical Oncology (ESMO)
Panhellenic Medical Association

Under the auspice of:



Invitation Letter

The recent, increasing amount of knowledge regarding lung cancer, especially in the field of basic science, holds promise for personalized treatment of these patients that would provide more effective and less toxic therapeutic approaches, improving the prognosis of the patients with thoracic malignancies. On the other hand, the immense bulk and the rapid recycling of the new information makes difficult its understanding, evaluation and interpretation by the clinicians. Therefore, the “translation” of our recently acquired knowledge from the lab bench to the bedside is neither smooth nor is it without obstructions, due to the existing “gaps” in our understanding and the often contradictory “signals” from clinical trials.

The success of our two previous meetings has prompted us to organize the **3rd Lung Cancer Network: “From the Bench to the Bedside”**. Our aim is to narrow the distance between the bench lab and the patient’s bed, between the clinical trials outcome and the routine practice, by bringing together basic scientists, clinical researchers and lung cancer specialists. Our multidisciplinary, international faculty will present the latest clinical data and provide treating physicians with practical information regarding the clinical significance of the histological, molecular and genetic profile of the tumor and how the implementation of targeted agents in the therapeutic algorithm changes the clinical practice of lung cancer patients.

Finally, we anticipate that our meeting, with the presence of our distinguished faculty, would provide the opportunity and motivation for discussions regarding the emerging therapies and set the pavement for the future research and strategies towards the personalized treatment of lung cancer patients.

We cordially welcome you all in Athens in January 31st & February 1st 2014 for a stimulating, innovative and educational meeting.

Learning Objectives

At the conclusion of our educational meeting, the participant will be able to:

- Recognize the clinical significance of molecular genotyping of lung cancer patients
- Understand the molecular pathways that hold promise for therapeutic intervention in lung cancer patients
- Discuss the optimal methodology of clinical trials in the era of translational research
- Recognize the importance of a multidisciplinary approach to the care lung cancer patients

Topics

- End points of translational research clinical trials
- Prognostic and predictive tumor markers
- The molecular pathology of non-smoker lung cancer patients
- Gender discrepancies in lung cancer
- NSCLC driver oncogenes
- EGFR mutation heterogeneity
- Newer generation TKIs inhibitors
- The Met, K-ras and mTOR/PI3K pathways

Target Audience

The meeting is designed for medical, radiation and surgical oncologists, pathologists, chest physicians, scientists, residents-in-training, fellows and other health care professionals interested in the basic and clinical research as well as in the management of thoracic cancers.

CME Accreditation - Auspice

The content of the meeting will be submitted for CME accreditation and we will request the auspice of ESMO, IASLC and ETOP.

The Chairs of the Meeting



Professor Kostas Syrigos



Professor Alex Adjei



Professor Rolf Stahel

Scientific Program

FRIDAY, January 31st

2014

15:30-16:00 Registrations

16:00-17:30 **Challenges for the pathologist and molecular biologist in the era of personalized medicine**

Chair: **Alex Adjei, Jean-Yves Douillard**

16:00-16:20 Optimal tissue acquisition and minimal requirements. **Keith Kerr**

16:20-16:40 The WHO classification on adenocarcinoma. **Elisabeth Brambilla**

16:40-17:00 The RAS challenge in lung cancer. **Amir Onn**

17:00-17:30 Discussion

17:30-18:00 **Coffee Break**

18:00-20:00 **Lung cancer clinical trials in the era of translational research**

Chair: **Rolf Stahel, Kostas Syrigos**

18:00-18:20 Coordinating the pathology lab with the clinical practice. **Niki Karachaliou**

18:20-18:40 Clinical trials endpoint: OS vs PFS. **Jean-Yves Douillard**

18:40-19:00 NSCLC prognostic and predictive markers. **David Rimm**

19:00-19:20 The evolving treatment landscape of NSCLC. **Alex Adjei**

19:20-19:40 Translating lung cancer biology to the clinic. **Adi Gazdar**

19:40-20:00 Discussion

20:00-20:15 **Opening Ceremony**

Chair: **Kostas Syrigos, Rolf Stahel**

Welcome addresses

Honorary award for their contribution to cancer patients.

Jean-Pierre Armand, Adi Gazdar

20:15-20:45 **Opening Lecture**

Early clinical development, a critical moment for drug success.

Jean-Pierre Armand

21:00 Welcome Reception

SATURDAY, February 1st

2014

09:00-10:00 **Immunotherapy of lung cancer**

Chair: **Solange Peters, Martin Reck**

09:00-09:20 Advances in vaccines immunotherapy. **Johan Vansteenkiste**

09:20-09:40 Anti-PD-1/Anti-PDL-1 antibodies in NSCLC. **Luis Paz-Ares**

09:40-10:00 Discussion

Sponsored by  Bristol-Myers Squibb

10:00-11:00 **Targeting the neovasculature in adenocarcinomas**

Chair: **Giorgio Scagliotti, Johan Vansteenkiste**

10:00-10:20 The expanding role of bevacizumab. **David Planchard**

10:20-10:40 Angiogenesis inhibition beyond bevasizumab. **Martin Reck**

10:40-11:00 Discussion

11:00-11:30 *Coffee Break*11:30-13:00 **The EGFR pathway in lung cancer**Chair: **Luis Paz-Ares, Fred Hirsch**11:30-11:50 Cetuximab in NSCLC: lessons for all. **Robert Pirker**11:50-12:10 Current status of EGFR TKIs. **Filippo de Marinis**12:10-12:20 Mechanisms of resistance to EGFR TKI and treatment strategies. **Rolf Stahel**12:20-12:40 Targeting HER2 and BRAF. **Solange Peters**

12:40-13:00 Discussion

13:00-14:00 **The EML4/ALK fusion protein**Chair: **Adi Gazdar, Enriqueta Felip**13:00-13:15 EML4/ALK pathway. **Ruth Palmer**13:15-13:30 Detection and monitoring of ALK- rearranged CTCs in ALK positive patients under treatment. **David Planchard**13:30-13:45 Optimal therapeutic algorithm for patients with EML4-ALK-positive disease. **Giorgio Scagliotti**13:45-14:00 Strategies to overcome crizotinib resistance. **Anne Chiang**14:00-15:30 **Symposium**14:00-14:05 Welcome. **Kostas Syrigos**14:05-14:15 Expanding the use of bevacizumab in patients with comorbidities: a case report. **Kostas Syrigos**14:15-14:35 Prolonging life expectancy: setting new hallmarks in the first-line adenocarcinoma. **David Planchard**14:35-14:45 Optimal use of targeted therapies in NSCLC: a case report. **Kostas Syrigos**14:45-15:05 The role of EGFR-TKIs in patients with EGFR wild-type NSCLC. **Martin Reck**15:05-15:25 The clinical relevance of MET pathway in NSCLC. **Hartmut Koeppen**15:25 Close. **Kostas Syrigos**Sponsored by 15:30-16:30 *Break*16:30-18:00 **Molecular biology of lung cancer**Chair: **Rolf Stahel, Silvia Novello**16:30-16:50 The clinical significance of circulating tumor cells. **Wilfried Eberhardt**16:50-17:10 The clinical significance of the MET pathway. **Enriqueta Felip**17:10-17:30 The clinical significance of the K-ras pathway in NSCLC. **Anne Chiang**17:30-17:50 The clinical significance of the PI3K pathway in NSCLC. **Alex Adjei**

17:50-18:00 Discussion

18:00-18:30 *Break*18:30-20:00 **Personalized treatment on lung cancer patients**Chair: **Alex Adjei, Kostas Syrigos**18:30-18:50 Squamous cell carcinomas. **Rafal Dziadziuszko**18:50-19:10 Small cell lung cancer. **Andrea Ardizzoni**19:10-19:20 Neuroendocrine tumors of the lung. **Dan Granberg**19:20-19:40 Gender discrepancies of lung cancer. **Silvia Novello**

19:40-20:00 Discussion

20:00 **Closing Ceremony**

Faculty

Alex A. Adjei

MD, PhD, Professor and Chair, Department of Medicine Katherine Anne Gioia, Chair in Cancer Medicine Senior, Vice-President for Clinical Research Roswell Park Cancer Institute, USA

Andrea Ardizzone

Dr, Head of Medical Oncology, University Hospital of Parma, Italy

Jean-Pierre Armand

Dr, MD, MSc, Medical Oncologist, Senior Consultant Oncology at Institute Curie and Institute Gustave Roussy, France

Elisabeth Brambilla

Professor of Pathology, Grenoble University Hospital, University Joseph Fourier Grenoble, France

Anne Chiang

MD, PhD, Assistant Professor, Department of Medicine, Yale University, School of Medicine, Chief Medical Officer, Smilow Cancer Hospital Network, USA

Filippo de Marinis

MD, Director, Thoracic Oncology Division, European Institute of Oncology (IEO), Milan, Italy

Jean-Yves Douillard

MD, PhD, Professor of Medical Oncology, Senior Staff Physician, Integrated Centers of Oncology René Gauducheau, France, Chair of Educational Committee ESMO

Rafal Dziadziuszko

Professor of Medicine, Deputy Chair, Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland

Wilfried Eberhardt

Dr, Department of Medical Oncology, West German Cancer Centre, University Hospital Essen, University Duisburg-Essen, Germany

Enriqueta Felip

MD, PhD, Head, Thoracic Oncology Unit, Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Adi Gazdar

Professor of Pathology and Deputy Director, Hamon Center for Therapeutic Oncology Research, The W. Ray Wallace Distinguished Chair in Molecular Oncology Research, University of Texas Southwestern Medical Center, USA

Dan Granberg

Dr, MD, PhD, Associate Professor, Senior Consultant, Department of Endocrine Oncology University Hospital, Uppsala, Sweden

Fred R. Hirsch

MD, PhD, Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, USA

Niki Karachaliou

Dr, Instituto Oncológico Dr. Rosell (IOR), Dexeus-Quiron University Hospital, Barcelona, Spain

Keith Kerr

Professor, Consultant Pathologist, Department of Pathology, Aberdeen Royal Infirmary, Professor of Pulmonary Pathology, Aberdeen University Medical School, Foresterhill, Aberdeen, UK

Koeppen Hartmut

MD, PhD, Staff Pathologist, Genentech

Silvia Novello

MD, PhD, Assistant Professor, Thoracic Oncology Unit, University of Turin, AUO San Luigi, Italy

Amir Onn

MD, Head, Department of Pulmonary Medicine and Pulmonary Oncology, Sheba Medical Center, Israel

Ruth Palmer

PhD, Professor in Molecular Genetics, Department of Molecular Biology, Umeå University, Sweden

Luis Paz-Ares

Dr, Chair of Oncology Department, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla, Spain

Solange Peters

MD, PhD, PD-MER, Department of Oncology, University of Lausanne, Switzerland

Robert Pirker

Dr, Professor of Medicine, Program Director for Lung Cancer, Department of Medicine I, Medical University of Vienna, Austria

David Planchard

MD, PhD, Associate Professor, Pulmonary-Oncologist, Department of Medical Oncology, Thoracic Group, Gustave-Roussy, France

Martin Reck

Dr, MD, PhD, Head of Department of Thoracic Oncology and Department of Clinical Trials, LungClinic Grosshansdorf, Member of the German Research Institute for Lung Research (DZL), Germany

David Rimm

MD, PhD, Professor, Director of Translational Pathology, Yale University School of Medicine, USA

Giorgio Scagliotti

Dr, Professor of Oncology, Head Department of Oncology, University of Torino, Italy

Rolf Stahel

MD, Head of the Center for Lung and Thoracic Oncology, Senior Staff Physician, Clinic of Oncology, University Hospital of Zürich, Titular Professor of Medicine, University of Zürich, Switzerland

Kostas Syrigos

MD, PhD, Professor and Head, Oncology Unit GPP, Athens School of Medicine, Visiting Professor of Thoracic Oncology, Yale School of Medicine, CT, USA

Johan Vansteenkiste

Dr, MD, PhD, Head of Clinic, Respiratory Oncology Unit, University Hospital KU Leuven, Leuven, Full Professor Internal Medicine, Faculty of Medicine, KU Leuven, Belgium

Scientific Information

Audiovisual – Technical Support

The meeting room will be equipped with data video projectors, laser pointers etc, for power point presentations. Technical Support Center will be available outside the “Hesperides” Hall. Technical staff will assist with the presentations. All speakers are kindly requested to submit their presentation at least 1 hour prior to their scheduled presentation.

Language

The official language of the congress is English.

CME Accreditation - Auspice

The content of the meeting will be submitted for CME accreditation. Accreditation will be received from the European Society for Medical Oncology (ESMO) and the Panhellenic Medical Association. The meeting will request the auspice of ESMO, IASLC and ETOP.

Name badges

All registered participants will receive name badges, which they are kindly requested to wear at all times. Each badge will have a barcode for monitoring the hours of attendance.

Certificate of Attendance

All registered participants who have attended at least 60% of the total scientific program will receive a certificate of attendance from the Secretariat Desk after the closing ceremony.

General Information

Organized by the

Oncology Center of Biomedical Education and Research
Oncology Unit GPP, Athens School of Medicine

Meeting website

www.lungcancernetwork.eu

Meeting Dates


31st January – 01st February 2014

Meeting Venue

Hilton Athens Hotel
46 Vassilissis Sofias Avenue
115 28 Athens, Greece
Tel.: 00 30 210 72 81 000



Conveniently situated in the heart of the city's commercial district, and just 25 minutes from the airport using the Athens Metro, the Hilton Athens' prime location and fabulous facilities make it the perfect spot for Athens meetings and exhibitions of all sizes.



The Meeting will take place at the "Hesperides" Hall.

The Meeting Secretariat will operate at the "Hesperides" foyer during the sessions.

Registration Cost

Type of Registration	Cost
Doctors*	400€
Residents	150€
Nurses	100€
Medical students	free

Registration cost includes:

- Admission to all sessions & exhibition area
- Meeting material
- Certificate of attendance
- Opening Ceremony & Welcome Reception
- Coffee breaks

* *ESMO & IASLC Members will receive a 20% discount.*

Please visit the meeting's official site to download the necessary forms.

Meeting's Secretariat



E.T.S. Events & Travel Solutions S.A.

El. Venizelou 154, 171 22 N. Smyrni - Athens, Greece

Tel.: +30 210 98 80 032 • Fax: +30 210 98 81 303

E-mail: ets@otenet.gr, ets@events.gr

Website: www.events.gr